Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infection
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects
The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5/X4-tropic virus
- Trial name
- NCT00197197
- Testing
- GW873140
- Where
- 12 sites in United States, Belgium
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
HIV-1-infection
Quality of Life of Taiwan People Living With HIV
To survey QoL and relevant factors in PLWH
- Trial name
- NCT04063306
- Testing
- none of intervention was given
- Where
- Taiwan
- Volunteers
- 550 people
- Sponsor
- Taiwan AIDS Nurse Society
HIV
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
The investigational product, ibalizumab, is a humanized IgG4 monoclonal antibody administered via intravenous infusion at 800 mg every 2 weeks or at 2000 mg every 4 weeks.
- Trial name
- TMB-202 (NCT00784147)
- Testing
- Ibalizumab
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 113 people
- Sponsor
- TaiMed Biologics Inc.
HIV-1 Infection
UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
This is a Phase 2, multi-center study, designed to evaluate the efficacy, safety, and tolerability of UB-421 in conjunction with a failing existing ART regimen for 1 week and optimized background therapy (OBT) for 24 weeks…
- Trial name
- NCT03164447
- Testing
- UB-421, Optimized background therapy (OBT)
- Volunteers
- 10 people
- Sponsor
- United BioPharma
Acquired Immunodeficiency Syndrome, HIV Infections
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
This study will evaluate the non-inferiority of Stribild® (elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single-tablet regimen (STR) relative to regimens consisting of a protease inhibitor (PI)…
- Trial name
- NCT01475838
- Testing
- PI, RTV, FTC/TDF
- Where
- 99 sites in United States, Austria and 10 more
- Volunteers
- 438 people
- Sponsor
- Gilead Sciences
HIV
Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay
The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV 1/2 Supplemental Assay, a single-use immunochromatographic assay for the confirmation and differentiation of individual antibodies to Human…
- Trial name
- NCT02401555
- Testing
- Geenius HIV1/2 Supplemental Assay
- Where
- 5 sites in United States
- Volunteers
- 419 people, healthy volunteers welcome
- Sponsor
- Bio-Rad Laboratories
HIV Infections
Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
- Trial name
- NCT00061243
- Testing
- HIV-1 DNA vaccine with protein vaccine boost
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
This study will continue to treat and collect safety and efficacy data on patients who participated in Glaxo-Wellcome's multi-center study on combination therapy with abacavir, amprenavir and efavirenz (A Phase II Study…
- Trial name
- NCT00001758
- Testing
- Abacavir, Amprenavir, Efavirenz
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials
The purpose of this study is to evaluate the safety and immune response to an HIV vaccine in healthy, HIV-uninfected adults who have participated in a previous HIV vaccine clinical trial and in healthy, HIV-uninfected adults who…
- Trial name
- NCT01376726
- Testing
- Sub C gp140 Vaccine, MF59C.1 Adjuvant
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Maraviroc Central Nervous System (CNS) Study
The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.
- Trial name
- NCT00982878
- Testing
- Maraviroc
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Imperial College London
Chronic HIV Infections
Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- NCT02902185
- Testing
- ART plus Chidamide
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
HIV-1-infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably…
- Trial name
- HIV-1 (NCT04404049)
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Volunteers
- 39 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
HIV Infections
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
This multicenter, retrospective, observational study will evaluate the therapeutic effectiveness of a strategy of induction with Fuzeon (enfuvirtide) within an optimized regimen of antiretroviral drugs in patients with HIV-1…
- Trial name
- NCT01902615
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers.
- Trial name
- NCT00376935
- Testing
- Palifermin
- Where
- 22 sites in United States
- Volunteers
- 99 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.
- Trial name
- NCT00004985
- Testing
- Capravirine, Nelfinavir mesylate
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Agouron Pharmaceuticals
HIV-1, Human Immunodeficiency Virus 1
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and anti-retroviral activity of MK-8510 monotherapy in anti-retroviral-naïve HIV-1 infected participants.
- Conditions
- HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
- Trial name
- NCT05700734
- Testing
- MK-8510
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
The objective of this study is to determine the long term safety and tolerability of an additional infusion of 10 billion VRX496 gene-modified CD4 T cells with a focus on evaluating additional therapeutic benefits with respect to…
- Trial name
- Rollover (NCT00622232)
- Testing
- VRX496-transduced autologous CD4 T cells
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- VIRxSYS Corporation
HIV-1 Infection
A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)
This study is designed to determine whether patients previously primed with Ad5 of MRKAd5 HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with MKRAd5 HIV-1 gag vaccine.
- Trial name
- NCT00894114
- Testing
- V520, Comparator: ALVAC-HIV vaccine
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
- Trial name
- NCT00002234
- Testing
- Efavirenz, Adefovir dipivoxil, Lamivudine
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a new microparticulate formulation of an HIV-1 MN PND peptide for oral administration in healthy, HIV-1 seronegative adult volunteers at low risk for infection.
- Trial name
- NCT00000798
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.